Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma. Phase I dose escalation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results